A Phase 3 interventional study of Budesonide MMX 6 mg Tablet and Placebo Tablet in Ulcerative Colitis, sponsored by Bausch Health Americas, Inc.. Completed at 58 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-08-31.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Bausch Health Companies Inc..
Among the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., this one is the 13th largest by enrollment, is one of 3 that started in 2008, is one of 14 in phase 3, and was the 9th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. are open now, in 1 country. Recruiting first, the newest first:
Bausch Health Americas, Inc. · Sites in United States
Ages 5–17
Bausch Health Americas, Inc.
Ages 5–17
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 273 across the 18 interventional studies. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 19 (73%) have results posted.
1 of the studies in Colitis, Ulcerative by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04314375Bausch Health Americas, Inc.Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity index (UCDAI) remission after 8 weeks of treatment.
Patients in remission at the End of Study visit will be given the opportunity to enter the 12-month Maintenance Phase study outlined in this protocol (CB-01-02/04). The End of Study visit in studies 01, 02, and 06 will be set as the Visit 1 (Day 0) of this study. There will be no interruption of study treatment between the parent studies and this study.
It is planned that approximately 150 patients will be enrolled in the study. Patients will be randomly assigned to two groups to receive either budesonide MMX 6 mg or placebo irrespective of the treatment assigned in studies 01, 02, or 06. Treatments will be administered once a day after breakfast for a maximum of 12 months or up to the occurrence of the first clinical relapse, where clinical relapse is defined as combined recurrence of rectal bleeding and stool frequency ≥ 1-2 stools/day above normal for the patient (score ≥ 1 in both UCDAI items).
During the study, patients will be assessed for safety and efficacy at Visit 1 and after 1, 3, 6, 9, and 12 months of treatment.
Patients will be contacted by telephone on a monthly basis for safety assessment. In case of occurrence of symptoms suggestive of clinical relapse, patients will attend an unscheduled visit at any time during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients fulfilling the following criteria are eligible for participation in the study:
Exclusion Criteria:
Patients who meet any of the following criteria at screening visit are to be excluded from study participation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
Drug: Budesonide MMX 6 mg Tablet
One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
Drug: Placebo Tablet
Budesonide MMX 6 mg Tablet once daily.
Placebo Tablet once daily.
Percentage of Participants Achieving Clinical Remission
Clinical remission was defined as the combined absence of recurrence of rectal bleeding and absence of increased stool frequency.
Time frame: 1, 3, 6, 9, and 12 months
Percentage of Participants With Clinical Relapse
Clinical relapse was defined as the recurrence of rectal bleeding and/or an abnormal stool frequency \[≥ 1-2 stools/day above normal for the participant. Clinical remission/relapse status was based on participant diary entries prior to each scheduled visit.
Time frame: 12 months
Percentage of Participants With Endoscopic Relapse
Endoscopic relapse was defined as an increase of ≥ 2 points in the Endoscopic Index score from the value calculated at baseline. The score is comprised of four components (granulated scattering reflected light, vascular pattern, vulnerability of mucosa, and mucosal damage). Scores range from 0 to 12, and higher scores indicate more severe (worse) endoscopic findings.
Time frame: 12 months
| Milestone | 2: Placebo | 1: Budesonide MMX® 6 mg |
|---|---|---|
| Started | 61 | 62 |
| Completed | 25 | 27 |
| Not completed | 36 | 35 |
Clinical remission was defined as the combined absence of recurrence of rectal bleeding and absence of increased stool frequency.
| percentage of participants | 2: Placebo | 1: Budesonide MMX® 6 mg |
|---|---|---|
| 1 month | 76.7 | 88.2 |
| 3 months | 92.0 | 96.8 |
| 6 months | 76.2 | 80.0 |
| 9 months | 86.7 | 95.0 |
| 12 months | 84.6 | 93.3 |
Clinical relapse was defined as the recurrence of rectal bleeding and/or an abnormal stool frequency \[≥ 1-2 stools/day above normal for the participant. Clinical remission/relapse status was based on participant diary entries prior to each scheduled visit.
| Participants | 2: Placebo | 1: Budesonide MMX® 6 mg |
|---|---|---|
| Percentage of Participants With Clinical Relapse | 19 | 12 |
Endoscopic relapse was defined as an increase of ≥ 2 points in the Endoscopic Index score from the value calculated at baseline. The score is comprised of four components (granulated scattering reflected light, vascular pattern, vulnerability of mucosa, and mucosal damage). Scores range from 0 to 12, and higher scores indicate more severe (worse) endoscopic findings.
| Participants | 2: Placebo | 1: Budesonide MMX® 6 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Relapse | 16 | 27 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2: Placebo | — | 1/61 (1.6%) | 30/61 (49.2%) |
| 1: Budesonide MMX® 6 mg | — | 1/62 (1.6%) | 34/62 (54.8%) |
| Event | 2: Placebo | 1: Budesonide MMX® 6 mg |
|---|---|---|
| Lobar pneumoniaInfections and infestations | 1/61 | 0/62 |
| HypertensionVascular disorders | 0/61 | 1/62 |
| Event | 2: Placebo | 1: Budesonide MMX® 6 mg |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 16/61 | 11/62 |
| Abdominal painGastrointestinal disorders | 5/61 | 6/62 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 5/61 | 1/62 |
| HeadacheNervous system disorders | 2/61 | 4/62 |
| Frequent bowel movementsGastrointestinal disorders | 1/61 | 4/62 |
| HaematocheziaBlood and lymphatic system disorders | 1/61 | 4/62 |
| ConstipationGastrointestinal disorders | 0/61 | 4/62 |
| Age, Continuous(years) | 2: Placebo | 1: Budesonide MMX® 6 mg | Total |
|---|---|---|---|
| Mean | 42.0 ± 11.77 | 42.9 ± 12.65 | 42.5 ± 12.21 |
| Sex: Female, Male(Participants) | 2: Placebo | 1: Budesonide MMX® 6 mg | Total |
|---|---|---|---|
| Female | 28 | 26 | 54 |
| Male | 33 | 36 | 69 |
The record gives a start of Dec 2008, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2020, 9 years 3 months after primary completion. A results delay was requested in Dec 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bausch Health Americas, Inc. →